COGNITION THERAPEUTICS INC

Explore Cognition Therapeutics’ market outlook: see its price trend, peer comparison, and upcoming preclinical milestones that could boost its $71M valuation.

Explore Cognition Therapeutics (CGTX) market insights and FDA‑aligned Phase 3 trial on zervimesine for dementia with Lewy bodies—latest stock performance, metrics, and corporate filing details.

CGTX stock dips 0.41% as Cognition Therapeutics’ share price falls below its 200‑day MA, amid mixed biotech market; investors eye a potential buying opportunity in early‑stage neurodegenerative therapies.